A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
← catalyst calendarNCT05391061 · readout in 460 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,100estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-07 | actual | When the study began enrolling |
| Primary completion | 2027-11-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-22 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis, Atopic
Intervention
- Drug: Abrocitinib — also filed as Cibinqo
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Adverse Events (AE's) according to frequency
measured Up to 52 weeks from the time of first treatment
Number of participants with Adverse Drug Reactions (ADR's) according to frequency
measured up to 52 weeks from the time of first treatment
Number of participants with unexpected AE's according to frequency
measured up to 52 weeks from the time of first treatment
Number of participants with unexpected ADR's according to frequency
measured up to 52 weeks from the time of first treatment
Number of participants with Serious Adverse Events (SAE's) according to frequency
measured up to 52 weeks from the time of first treatment
Number of participants with Serious Adverse Drug Reactions (SADR's) according to frequency
measured up to 52 weeks from the time of first treatment
Number of participants with Adverse Events of Special Interest (AESI) according to frequency
measured up to 52 weeks from the time of first treatment
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed